{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T16:52:23Z","timestamp":1783702343694,"version":"3.55.0"},"reference-count":44,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,11,9]],"date-time":"2022-11-09T00:00:00Z","timestamp":1667952000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100017695","name":"Health Commission of Hunan Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017695","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Introduction:<\/jats:bold> Antibody\u2013drug conjugates (ADCs) produce unparalleled efficacy in refractory neoplasms but can also lead to serious toxicities. Although ADC-related sepsis has been reported, the clinical features are not well characterized in real-world studies.<\/jats:p><jats:p><jats:bold>Objective:<\/jats:bold> The aim of this study was to identify the association between ADCs and sepsis using FAERS data and uncover the clinical characteristics of ADC-related sepsis.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> We performed disproportionality analysis using FAERS data and compared rates of sepsis in cancer patients receiving ADCs vs. other regimens. Associations between ADCs and sepsis were assessed using reporting odds ratios (RORs) and information component (IC). For each treatment group, we detected drug interaction signals, and conducted subgroup analyses (age, gender, and regimens) and sensitivity analyses.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> A total of 24,618 cases were reported with ADCs between Q1, 2004 and Q3, 2021. Sepsis, septic shock, multiple organ dysfunction syndrome, and other sepsis-related toxicities were significantly associated with ADCs than other drugs in this database. Sepsis and multiple organ dysfunction syndrome have the highest safety concerns with ADCs compared with other anticancer monotherapies. Gemtuzumab ozogamicin and inotuzumab ozogamicin showed increased safety risks than other ADCs. For the top nine ADC-related sepsis, males showed higher sepsis safety concern than females (<jats:italic>p<\/jats:italic> &amp;lt;0.001); however, age did not exert influence on the risk of sepsis. We identified that 973 of 2,441 (39.9%) cases had acute myeloid leukemia (AML), and 766 of 2613 (29.3%) cases on ADCs died during therapy. Time-to-onset analysis indicated ADC-related sepsis is prone to occur within a month after administration. Co-administration of ADCs with colony-stimulating factors, proton pump inhibitors, H2-receptor antagonists, or CYP3A4\/5 inhibitors showed to synergistically increase the risk of sepsis-related toxicities.<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> Antibody\u2013drug conjugates may increase the risk of sepsis in cancer patients, leading to high mortality. Further studies are warranted to characterize the underlying mechanisms and design preventive measures for ADC-related sepsis.<\/jats:p>","DOI":"10.3389\/fphar.2022.967017","type":"journal-article","created":{"date-parts":[[2022,11,9]],"date-time":"2022-11-09T08:33:17Z","timestamp":1667982797000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":15,"title":["Do antibody\u2013drug conjugates increase the risk of sepsis in cancer patients? A pharmacovigilance study"],"prefix":"10.3389","volume":"13","author":[{"given":"Shuang","family":"Xia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Chang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Kun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bi-Kui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Sheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayur","family":"Sarangdhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiro","family":"Noguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miao","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,11,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1248\/bpb.b19-00156","article-title":"Evaluation of the expression time of ganciclovir-induced adverse events using JADER and FAERS","volume":"42","author":"Ando","year":"2019","journal-title":"Biol. Pharm. Bull."},{"key":"B2","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s002280050466","article-title":"A Bayesian neural network method for adverse drug reaction signal generation","volume":"54","author":"Bate","year":"1998","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1046\/j.1365-2125.2002.01694.x","article-title":"Does age increase the risk of adverse drug reactions?","volume":"54","author":"Begaud","year":"2002","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"R58","DOI":"10.1186\/cc10031","article-title":"Granulocyte-colony stimulating factor (G-CSF) and granulocyte-macrophage colony stimulating factor (GM-CSF) for sepsis: a meta-analysis","volume":"15","author":"Bo","year":"2011","journal-title":"Crit. Care"},{"key":"B5","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/S0140-6736(18)30696-2","article-title":"Sepsis and septic shock","volume":"392","author":"Cecconi","year":"2018","journal-title":"Lancet"},{"key":"B6","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/S0140-6736(19)31774-X","article-title":"Antibody-drug conjugates for cancer","volume":"394","author":"Chau","year":"2019","journal-title":"Lancet"},{"key":"B7","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s13045-021-01035-z","article-title":"Antibody-drug conjugates in solid tumors: a look into novel targets","volume":"14","author":"Criscitiello","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1111\/bcp.12596","article-title":"Adverse drug reactions in special populations - the elderly","volume":"80","author":"Davies","year":"2015","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/s41408-020-00345-8","article-title":"Inotuzumab ozogamicin for relapsed\/refractory acute lymphoblastic leukemia: outcomes by disease burden","volume":"10","author":"DeAngelo","year":"2020","journal-title":"Blood Cancer J."},{"key":"B10","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/s41571-021-00470-8","article-title":"Unlocking the potential of antibody-drug conjugates for cancer therapy","volume":"18","author":"Drago","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1111\/dom.13130","article-title":"Dipeptidyl peptidase-4 inhibitors moderate the risk of genitourinary tract infections associated with sodium-glucose co-transporter-2 inhibitors","volume":"20","author":"Fadini","year":"2018","journal-title":"Diabetes Obes. Metab."},{"key":"B12","doi-asserted-by":"publisher","first-page":"e000725","DOI":"10.1136\/bmjdrc-2019-000725","article-title":"Pharmacovigilance assessment of the association between Fournier's gangrene and other severe genital adverse events with SGLT-2 inhibitors","volume":"7","author":"Fadini","year":"2019","journal-title":"BMJ Open Diabetes Res. Care"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1097\/CCM.0000000000003896","article-title":"Epidemiology and outcomes of cancer-related versus non-cancer-related sepsis hospitalizations","volume":"47","author":"Hensley","year":"2019","journal-title":"Crit. Care Med."},{"key":"B14","doi-asserted-by":"publisher","first-page":"420","DOI":"10.3390\/healthcare10030420","article-title":"A standardized dataset of a spontaneous adverse event reporting system","volume":"10","author":"Khaleel","year":"2022","journal-title":"Healthcare"},{"key":"B15","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1007\/s11739-018-02015-x","article-title":"Risk factors for extended-spectrum beta-lactamase-producing Enterobacteriaceae infection causing septic shock in cancer patients with chemotherapy-induced febrile neutropenia","volume":"14","author":"Kim","year":"2019","journal-title":"Intern. Emerg. Med."},{"key":"B16","doi-asserted-by":"publisher","first-page":"202","DOI":"10.6004\/jnccn.2008.0017","article-title":"Infectious complications associated with immunomodulating monoclonal antibodies used in the treatment of hematologic malignancy","volume":"6","author":"Koo","year":"2008","journal-title":"J. Natl. Compr. Canc. Netw."},{"key":"B17","first-page":"634","article-title":"In vivo priming with granulocyte colony-stimulating factor possibly enhances the effect of gemtuzumab-ozogamicin in acute myeloid leukemia: results of a pilot study","volume":"89","author":"Leone","year":"2004","journal-title":"Haematologica"},{"key":"B18","doi-asserted-by":"publisher","first-page":"e228","DOI":"10.1097\/CAD.0000000000001191","article-title":"Caution the arrhythmia association with antibody-drug conjugates: a pharmacovigilance study","volume":"33","author":"Li","year":"2022","journal-title":"Anticancer. Drugs"},{"key":"B19","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1007\/s40264-021-01069-9","article-title":"Risk minimization of antibody-drug conjugates in Oncology: A review","volume":"44","author":"Lievano","year":"2021","journal-title":"Drug Saf."},{"key":"B20","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.pharmthera.2019.04.008","article-title":"Potential mechanisms of target-independent uptake and toxicity of antibody-drug conjugates","volume":"200","author":"Mahalingaiah","year":"2019","journal-title":"Pharmacol. Ther."},{"key":"B21","doi-asserted-by":"publisher","first-page":"45","DOI":"10.6004\/jnccn.2021.7046","article-title":"Outcomes and predictors of 28-day mortality in patients with hematologic malignancies and septic shock defined by sepsis-3 criteria","volume":"20","author":"Manjappachar","year":"2022","journal-title":"J. Natl. Compr. Canc. Netw."},{"key":"B22","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s10637-017-0520-6","article-title":"Clinical toxicity of antibody drug conjugates: a meta-analysis of payloads","volume":"36","author":"Masters","year":"2018","journal-title":"Invest. New Drugs"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.3389\/fphar.2019.01319","article-title":"Review of statistical methodologies for detecting drug-drug interactions using spontaneous reporting systems","volume":"10","author":"Noguchi","year":"2019","journal-title":"Front. Pharmacol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1007\/s11095-020-02801-3","article-title":"Comparison of signal detection algorithms based on frequency statistical model for drug-drug interaction using spontaneous reporting systems","volume":"37","author":"Noguchi","year":"2020","journal-title":"Pharm. Res."},{"key":"B25","doi-asserted-by":"publisher","first-page":"bbab347","DOI":"10.1093\/bib\/bbab347","article-title":"Detection algorithms and attentive points of safety signal using spontaneous reporting systems as a clinical data source","volume":"22","author":"Noguchi","year":"2021","journal-title":"Brief. Bioinform."},{"key":"B26","doi-asserted-by":"publisher","first-page":"3057","DOI":"10.1002\/sim.3247","article-title":"A statistical methodology for drug-drug interaction surveillance","volume":"27","author":"Noren","year":"2008","journal-title":"Stat. Med."},{"key":"B27","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1177\/0962280211403604","article-title":"Shrinkage observed-to-expected ratios for robust and transparent large-scale pattern discovery","volume":"22","author":"Noren","year":"2013","journal-title":"Stat. Methods Med. Res."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1001\/jamaoncol.2017.4526","article-title":"EGFR-TKI-Associated interstitial pneumonitis in nivolumab-treated patients with non-small cell lung cancer","volume":"4","author":"Oshima","year":"2018","journal-title":"JAMA Oncol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","article-title":"Enfortumab vedotin in previously treated advanced urothelial carcinoma","volume":"384","author":"Powles","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"B30","doi-asserted-by":"publisher","first-page":"78","DOI":"10.3760\/cma.j.cn112152-20201112-00981","article-title":"Expert consensus on the clinical application of antibody drug conjugates in the treatment of malignant tumors (2020 Edition)","volume":"43","year":"2021","journal-title":"Zhonghua Zhong Liu Za Zhi"},{"key":"B31","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1002\/pds.1001","article-title":"The reporting odds ratio and its advantages over the proportional reporting ratio","volume":"13","author":"Rothman","year":"2004","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1016\/S1470-2045(18)30608-9","article-title":"Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study","volume":"19","author":"Salem","year":"2018","journal-title":"Lancet. Oncol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1038\/nbt.3623","article-title":"Data mining differential clinical outcomes associated with drug regimens using adverse event reporting data","volume":"34","author":"Sarangdhar","year":"2016","journal-title":"Nat. Biotechnol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1111\/cts.12899","article-title":"Therapeutic opportunities for intestinal angioectasia- targeting PPAR\u03b3 and oxidative stress","volume":"14","author":"Sarangdhar","year":"2021","journal-title":"Clin. Transl. Sci."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1002\/lt.23918","article-title":"First experience with brentuximab vedotin in posttransplant lymphoproliferative disorder after liver transplantation: complete remission followed by lethal sepsis","volume":"20","author":"Schaefer","year":"2014","journal-title":"Liver Transpl."},{"key":"B36","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1200\/JCO.19.00172","article-title":"Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma","volume":"38","author":"Sehn","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"2931","DOI":"10.1080\/10428194.2020.1791846","article-title":"Primary prophylaxis with G-CSF may improve outcomes in patients with newly diagnosed stage III\/IV Hodgkin lymphoma treated with brentuximab vedotin plus chemotherapy","volume":"61","author":"Straus","year":"2020","journal-title":"Leuk. Lymphoma"},{"key":"B38","doi-asserted-by":"publisher","first-page":"65","DOI":"10.4103\/jipo.jipo_12_19","article-title":"Rheumatic and musculoskeletal adverse events with immune checkpoint inhibitors: Data from the United States food and drug administration adverse event reporting system","volume":"2","author":"Suarez-Almazor","year":"2019","journal-title":"J. Immunother. Precis. Oncol."},{"key":"B39","unstructured":"The UMC measures of disproportionate reporting2016"},{"key":"B40","doi-asserted-by":"publisher","first-page":"4809","DOI":"10.1038\/s41467-020-18396-7","article-title":"Transcriptomic profiling of human cardiac cells predicts protein kinase inhibitor-associated cardiotoxicity","volume":"11","author":"van Hasselt","year":"2020","journal-title":"Nat. Commun."},{"key":"B41","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1002\/pds.3226","article-title":"Using time-to-onset for detecting safety signals in spontaneous reports of adverse events following immunization: a proof of concept study","volume":"21","author":"Van Holle","year":"2012","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"B42","doi-asserted-by":"publisher","first-page":"D1074","DOI":"10.1093\/nar\/gkx1037","article-title":"DrugBank 5.0: a major update to the DrugBank database for 2018","volume":"46","author":"Wishart","year":"2018","journal-title":"Nucleic Acids Res."},{"key":"B43","doi-asserted-by":"publisher","first-page":"801199","DOI":"10.3389\/fonc.2021.801199","article-title":"Cutaneous toxicity associated with enfortumab vedotin: a real-word study leveraging U.S. Food and drug administration adverse event reporting system","volume":"11","author":"Yang","year":"2021","journal-title":"Front. Oncol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"105292","DOI":"10.1016\/j.tiv.2021.105292","article-title":"Proton pump inhibitors interfere with the anti-tumor potency of RC48ADC","volume":"79","author":"Zhang","year":"2022","journal-title":"Toxicol. Vitro."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.967017\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,16]],"date-time":"2022-11-16T17:25:36Z","timestamp":1668619536000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.967017\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,9]]},"references-count":44,"alternative-id":["10.3389\/fphar.2022.967017"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2022.967017","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,9]]},"article-number":"967017"}}